

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ACZONE® Gel, 7.5% safely and effectively. See full prescribing information for ACZONE® Gel, 7.5%.

ACZONE® (dapsone) Gel, 7.5%, for topical use
Initial U.S. Approval: 1955

INDICATIONS AND USAGE

ACZONE® Gel, 7.5%, is a sulfone indicated for the topical treatment of acne vulgaris in patients 12 years of age and older (1).

DOSAGE AND ADMINISTRATION

- Apply once daily (2).
- Apply approximately a pea-sized amount of ACZONE Gel, 7.5%, in a thin layer to the entire face. A thin layer can also be applied to other affected areas (2).
- If there is no improvement after 12 weeks, treatment with ACZONE Gel, 7.5% should be reassessed (2).
- For topical use only. Not for oral, ophthalmic, or intravaginal use (2).

DOSAGE FORMS AND STRENGTHS

Gel, 7.5% (3).

CONTRAINDICATIONS

None (4).

WARNINGS AND PRECAUTIONS

- Methemoglobinemia: Cases of methemoglobinemia have been reported. Discontinue ACZONE Gel if signs of methemoglobinemia occur (5.1).
- Hemolysis: Some patients with Glucose-6-phosphate Dehydrogenase (G6PD) deficiency using topical dapsone developed laboratory changes suggestive of hemolysis (5.1)(8.6).

ADVERSE REACTIONS

Most common (incidence \geq 0.9%) adverse reactions are application site dryness and pruritus (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Trimethoprim/sulfamethoxazole (TMP/SMX) increases the systemic level of dapsone and its metabolites (7.1).
- Topical benzoyl peroxide used at the same time as ACZONE Gel, 7.5% may result in temporary local yellow or orange skin discoloration (7.2).

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 02/2016

FULL PRESCRIBING INFORMATION: CONTENTS*

- | | |
|--|---|
| 1 INDICATIONS AND USAGE | 8 USE IN SPECIFIC POPULATIONS |
| 2 DOSAGE AND ADMINISTRATION | 8.1 Pregnancy |
| 3 DOSAGE FORMS AND STRENGTHS | 8.3 Nursing Mothers |
| 4 CONTRAINDICATIONS | 8.4 Pediatric Use |
| 5 WARNINGS AND PRECAUTIONS | 8.5 Geriatric Use |
| 5.1 Hematological Effects | 8.6 Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency |
| 5.2 Peripheral Neuropathy | 11 DESCRIPTION |
| 5.3 Skin Reactions | 12 CLINICAL PHARMACOLOGY |
| 6 ADVERSE REACTIONS | 12.1 Mechanism of Action |
| 6.1 Clinical Studies Experience | 12.3 Pharmacokinetics |
| 6.2 Experience with Oral Use of Dapsone | 12.4 Microbiology |
| 6.3 Postmarketing Experience | 13 NONCLINICAL TOXICOLOGY |
| 7 DRUG INTERACTIONS | 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility |
| 7.1 Trimethoprim-Sulfamethoxazole | 14 CLINICAL STUDIES |
| 7.2 Topical Benzoyl Peroxide | 16 HOW SUPPLIED/STORAGE AND HANDLING |
| 7.3 Drug Interactions with Oral Dapsone | 17 PATIENT COUNSELING INFORMATION |
| 7.4 Concomitant Use with Drugs that Induce Methemoglobinemia | |

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

ACZONE[®] (dapson) Gel, 7.5%, is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

2 DOSAGE AND ADMINISTRATION

For topical use only. Not for oral, ophthalmic, or intravaginal use.

After the skin is gently washed and patted dry, apply approximately a pea-sized amount of **ACZONE** Gel, 7.5%, in a thin layer to the entire face once daily. In addition, a thin layer may be applied to other affected areas once daily. Rub in **ACZONE** Gel, 7.5%, gently and completely.

If there is no improvement after 12 weeks, treatment with **ACZONE** Gel, 7.5% should be reassessed (2).

3 DOSAGE FORMS AND STRENGTHS

Gel, 7.5%. Each gram of **ACZONE** Gel, 7.5% contains 75 mg of dapson in an off-white to yellow gel with suspended particles.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Hematological Effects

Methemoglobinemia

Cases of methemoglobinemia, with resultant hospitalization, have been reported postmarketing in association with twice daily dapson gel, 5%, treatment. Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. Avoid use of **ACZONE** Gel, 7.5% in those patients with congenital or idiopathic methemoglobinemia.

Signs and symptoms of methemoglobinemia may be delayed some hours after exposure. Initial signs and symptoms of methemoglobinemia are characterized by a slate grey cyanosis seen in e.g., buccal mucous membranes, lips, and nail beds. Advise patients to discontinue **ACZONE** Gel, 7.5% and seek immediate medical attention in the event of cyanosis.

Dapson can cause elevated methemoglobin levels particularly in conjunction with methemoglobin-inducing agents [*see Drug Interactions (7.4)*].

Hemolysis

Oral dapson treatment has produced dose-related hemolysis and hemolytic anemia. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are more prone to hemolysis with the use of certain drugs. G6PD deficiency is most prevalent in populations of African, South Asian, Middle Eastern, and Mediterranean ancestry.

In clinical trials, there was no evidence of clinically relevant hemolysis or hemolytic anemia in subjects treated with topical dapson. Some subjects with G6PD deficiency using dapson gel, 5 %, twice daily developed laboratory changes suggestive of hemolysis [*see Use in Specific Populations (8.6)*].

Discontinue **ACZONE Gel, 7.5%**, if signs and symptoms suggestive of hemolytic anemia occur. Avoid use of **ACZONE Gel, 7.5%** in patients who are taking oral dapsone or antimalarial medications because of the potential for hemolytic reactions. Combination of **ACZONE Gel, 7.5%**, with trimethoprim/sulfamethoxazole (TMP/SMX) may increase the likelihood of hemolysis in patients with G6PD deficiency [see *Drug Interactions (7.1)*].

5.2 Peripheral Neuropathy

Peripheral neuropathy (motor loss and muscle weakness) has been reported with oral dapsone treatment. No events of peripheral neuropathy were observed in clinical trials with topical dapsone treatment.

5.3 Skin Reactions

Skin reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarlatiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria) have been reported with oral dapsone treatment. These types of skin reactions were not observed in clinical trials with topical dapsone treatment.

6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A total of 2161 subjects were treated with **ACZONE Gel, 7.5%**, for 12 weeks in 2 controlled clinical trials. The population ranged in age from 12 to 63 years, was 56% female, and 58% Caucasian. Adverse drug reactions that were reported in at least 0.9% of subjects treated with **ACZONE Gel, 7.5%** appear in Table 1 below.

Table 1 Adverse Reactions Occurring in at Least 0.9% of Subjects with Acne Vulgaris in 12-week Controlled Clinical Trials

	ACZONE Gel, 7.5% (N=2161)	Vehicle (N=2175)
Application Site Dryness	24 (1.1%)	21 (1.0%)
Application Site Pruritus	20 (0.9%)	11 (0.5%)

6.2 Experience with Oral Use of Dapsone

Although not observed in the clinical trials with topical dapsone, serious adverse reactions have been reported with oral use of dapsone, including agranulocytosis, hemolytic anemia, peripheral neuropathy (motor loss and muscle weakness), and skin reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarlatiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria).

6.3 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of topical dapsone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Methemoglobinemia has been identified during postmarketing use of topical dapsone [see *Warnings and Precautions (5.1)*].

7 DRUG INTERACTIONS

No formal drug-drug interaction studies were conducted with **ACZONE Gel, 7.5%**.

7.1 Trimethoprim-Sulfamethoxazole

A drug-drug interaction study evaluated the effect of the use of dapsons gel, 5% in combination with double strength (160 mg/800 mg) trimethoprim-sulfamethoxazole (TMP/SMX). During co-administration, systemic levels of TMP and SMX were essentially unchanged, however, levels of dapsons and its metabolites increased in the presence of TMP/SMX. The systemic exposure from **ACZONE** Gel, 7.5% is expected to be about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX.

7.2 Topical Benzoyl Peroxide

Topical application of dapsons gel followed by benzoyl peroxide in patients with acne vulgaris may result in a temporary local yellow or orange discoloration of the skin and facial hair.

7.3 Drug Interactions with Oral Dapsons

Certain concomitant medications (such as rifampin, anticonvulsants, St. John's wort) may increase the formation of dapsons hydroxylamine, a metabolite of dapsons associated with hemolysis. With oral dapsons treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions.

7.4 Concomitant Use with Drugs that Induce Methemoglobinemia

Concomitant use of **ACZONE** Gel, 7.5% with drugs that induce methemoglobinemia such as sulfonamides, acetaminophen, acetanilide, aniline dyes, benzocaine, chloroquine, dapsons, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine, and quinine may increase the risk for developing methemoglobinemia [*see Warnings and Precautions (5.1)*].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Teratogenic Effects: Pregnancy Category C

There are no adequate and well controlled studies in pregnant women. **ACZONE** Gel, 7.5%, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Dapsons has been shown to have an embryocidal effect in rats and rabbits when administered orally during the period of organogenesis in doses of 75 mg/kg/day and 150 mg/kg/day, respectively (approximately 1400 and 425 times, respectively, the systemic exposure that is associated with the maximum recommended human dose (MRHD) of **ACZONE** Gel, 7.5%, based on AUC comparisons). These effects may have been secondary to maternal toxicity.

8.3 Nursing Mothers

Although systemic absorption of dapsons following topical application of **ACZONE** Gel, 7.5%, is minimal relative to oral dapsons administration, it is known that dapsons is excreted in human milk. Because of the potential for oral dapsons to cause adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue **ACZONE** Gel, 7.5%, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and efficacy was evaluated in 1066 subjects aged 12-17 years old treated with **ACZONE** Gel, 7.5% in the clinical trials. The safety profile for **ACZONE** Gel, 7.5%, was similar to the vehicle control group. Safety and effectiveness of **ACZONE** Gel, 7.5%, have not been established in pediatric patients below the age of 12 years.

8.5 Geriatric Use

Clinical trials of **ACZONE** Gel, 7.5% did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects.


8.6 Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency

Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be more prone to methemoglobinemia and hemolysis [see *Warnings and Precautions (5.1)*].

ACZONE Gel, 5% and vehicle were evaluated in a randomized, double-blind, cross-over design clinical study of 64 subjects with G6PD deficiency and acne vulgaris. Subjects were Black (88%), Asian (6%), Hispanic (2%) or of other racial origin (5%). Blood samples were taken at Baseline, Week 2, and Week 12 during both vehicle and **ACZONE** Gel, 5% treatment periods. Some of these subjects developed laboratory changes suggestive of hemolysis, but there was no evidence of clinically significant hemolytic anemia in this study [see *Warnings and Precautions (5.1)*].

11 DESCRIPTION

ACZONE (dapson) Gel, 7.5%, contains dapsone, a sulfone, in an aqueous gel base for topical dermatologic use. **ACZONE** Gel, 7.5% is an off-white to yellow gel with suspended particles. Chemically, dapsone has an empirical formula of C₁₂H₁₂N₂O₂S. It is a white or slightly yellow-white, crystalline powder that has a molecular weight of 248.30. Dapsone's chemical name is 4-[(4-aminobenzene) sulfonyl] aniline and its structural formula is:



Each gram of **ACZONE** Gel, 7.5%, contains 75 mg of dapsone, USP, in a gel of diethylene glycol monoethyl ether, methylparaben, acrylamide/sodium acryloyldimethyl taurate copolymer, isohexadecane, polysorbate 80, and purified water.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of dapsone gel in treating acne vulgaris is not known.

12.3 Pharmacokinetics

In a pharmacokinetic study, male and female subjects 16 years of age or older with acne vulgaris (N=19) received 2 grams of **ACZONE** Gel, 7.5%, topically to the face, upper chest, upper back and shoulders once daily for 28 days. Steady state for dapsone was reached within 7 days of dosing. On Day 28, the mean dapsone maximum plasma concentration (C_{max}) and area under the concentration-time curve from 0 to 24 hours post dose (AUC_{0-24h}) were 13.0 ± 6.8 ng/mL and 282 ± 146 ng·h/mL, respectively. The systemic exposure from **ACZONE** Gel, 7.5% is expected to be about 1% of that from a 100 mg oral dose.

Long-term safety studies were not conducted with **ACZONE** Gel, 7.5%, however, in a long-term clinical study of dapsone gel, 5% treatment (twice daily), periodic blood samples were collected up to 12 months to determine systemic exposure of dapsone and its metabolites in approximately 500 subjects. Based on the measurable dapsone concentrations from 408 subjects (M=192, F=216), obtained at Month 3, neither gender nor race appeared to affect the pharmacokinetics of dapsone. Similarly, dapsone exposures were approximately the same between the age groups of 12-15 years (N=155) and those greater than or equal to 16 years (N=253). There was no evidence of increasing systemic exposure to dapsone over the study year in these subjects.

12.4 Microbiology

In Vivo Activity: No microbiology or immunology studies were conducted during **ACZONE** Gel, 7.5% clinical studies.

Drug Resistance: No dapsones resistance studies were conducted during dapsones gel clinical studies. Because no such studies were done, there are no data available as to whether dapsones treatment may have resulted in decreased susceptibility of *Propionibacterium acnes*, an organism associated with acne, or to other antimicrobials that may be used to treat acne. Therapeutic resistance to dapsones has been reported for *Mycobacterium leprae*, when patients have been treated with oral dapsones.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Dapsones was not carcinogenic to rats when orally administered for a lifetime at dose levels up to 15 mg/kg/day (approximately 340 times the systemic exposure that is associated with the MRHD of **ACZONE** Gel, 7.5%, based on AUC comparisons).

No evidence of potential to induce carcinogenicity was obtained in a dermal study in which dapsones gel was topically applied to Tg.AC transgenic mice for approximately 26 weeks. Dapsones concentrations of 3%, 5%, and 10% were evaluated; 3% material was judged to be the maximum tolerated dosage.

Topical gels that contained dapsones at concentrations up to 5% did not increase the rate of formation of ultraviolet light-induced skin tumors when topically applied to hairless mice in a 12-month photocarcinogenicity study.

Dapsones was not mutagenic in a bacterial reverse mutation assay (Ames test) using *S. typhimurium* and *E. coli*, with and without metabolic activation, and was negative in a micronucleus assay conducted in mice. Dapsones increased both numerical and structural aberrations in a chromosome aberration assay conducted with Chinese hamster ovary (CHO) cells.

The effects of dapsones on fertility and general reproduction performance were assessed in male and female rats following oral (gavage) dosing. Dapsones reduced sperm motility at dosages of 3 mg/kg/day or greater (approximately 22 times the systemic exposure that is associated with the MRHD of **ACZONE** Gel, 7.5%, based on AUC comparisons). The mean numbers of embryo implantations and viable embryos were significantly reduced in untreated females mated with males that had been dosed at 12 mg/kg/day or greater (approximately 187 times the systemic exposure that is associated with the MRHD of **ACZONE** Gel, 7.5%, based on AUC comparisons), presumably due to reduced numbers or effectiveness of sperm, indicating impairment of fertility. Dapsones had no effect on male fertility at dosages of 2 mg/kg/day or less (approximately 15 times the systemic exposure that is associated with the MRHD of **ACZONE** Gel, 7.5%, based on AUC comparisons). When administered to female rats at a dosage of 75 mg/kg/day (approximately 1400 times the systemic exposure that is associated with the MRHD of **ACZONE** Gel, 7.5%, based on AUC comparisons) for 15 days prior to mating and for 17 days thereafter, dapsones reduced the mean number of implantations, increased the mean early resorption rate, and reduced the mean litter size. These effects were probably secondary to maternal toxicity.

Dapsones was assessed for effects on perinatal/postnatal pup development and postnatal maternal behavior and function in a study in which dapsones was orally administered to female rats daily beginning on the seventh day of gestation and continuing until the twenty-seventh day postpartum. Maternal toxicity (decreased body weight and food consumption) and developmental effects (increase in stillborn pups and decreased pup weight) were seen at a dapsones dose of 30 mg/kg/day (approximately 560 times the systemic exposure that is associated with

the MRHD of **ACZONE** Gel, 7.5%, based on AUC comparisons). No effects were observed on the viability, physical development, behavior, learning ability, or reproductive function of surviving pups.

14 CLINICAL STUDIES

The safety and efficacy of once daily use of **ACZONE** Gel, 7.5%, was assessed in two 12-week multicenter, randomized, double-blind, vehicle-controlled studies. Efficacy was assessed in a total of 4340 subjects 12 years of age and older. The majority of the subjects had moderate acne vulgaris, 20 to 50 inflammatory and 30 to 100 non-inflammatory lesions at baseline, who were randomized to receive either **ACZONE** Gel, 7.5% or vehicle.

Treatment response was defined at Week 12 as the proportion of subjects who were rated “none” or “minimal” with at least a two-grade improvement from baseline on the Global Acne Assessment Score (GAAS), and mean absolute change from baseline in both inflammatory and non-inflammatory lesion counts. A GAAS score of “none” corresponded to no evidence of facial acne vulgaris. A GAAS score of “minimal” corresponded to a few non-inflammatory lesions (comedones) being present and to a few inflammatory lesions (papules/pustules) that may be present.

The GAAS success rate, mean reduction, and percent reduction in acne lesion counts from baseline after 12 weeks of treatment are presented in the following table.

Table 3 Clinical Efficacy of ACZONE® Gel at Week 12 in Subjects with Acne Vulgaris

	Trial 1		Trial 2	
	ACZONE® Gel, 7.5% (N=1044)	Vehicle (N=1058)	ACZONE® Gel, 7.5% (N=1118)	Vehicle (N=1120)
Global Acne Assessment Score				
GAAS Success (Score 0 or 1)	30%	21%	30%	21%
Inflammatory Lesions				
Mean absolute reduction	16.1	14.3	15.6	14.0
Mean percent reduction	56%	49%	54%	48%
Non-inflammatory Lesions				
Mean absolute reduction	20.7	18.0	20.8	18.7
Mean percent reduction	45%	39%	46%	41%

16 HOW SUPPLIED/STORAGE AND HANDLING

ACZONE Gel is an off-white to yellow gel with suspended particles. It is supplied in an airless pump containing a polypropylene bottle with a high density polyethylene piston.

ACZONE (dapson) Gel, 7.5%, is supplied in the following sizes:

NDC 0023-5206-30	30 gram pump
NDC 0023-5206-60	60 gram pump
NDC 0023-5206-90	90 gram pump

Storage: Store at 20°C-25°C (68°F-77°F), excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature]. Protect from freezing.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hematological Effects

- Inform patients that methemoglobinemia can occur with topical dapson treatment. Advise patients to seek immediate medical attention if they develop cyanosis [see *Warnings and Precautions (5.1)*].
- Inform patients who have G6PD deficiency that hemolytic anemia may occur with topical dapson treatment. Advise patients to seek medical attention if they develop signs and symptoms suggestive of hemolytic anemia [see *Warnings and Precautions (5.1)*].

Important Administration Instructions

- Advise patients to apply ACZONE Gel, 7.5%, once daily to the entire face [see *Dosage and Administration (2)*].
- ACZONE Gel, 7.5% is for topical use only.
- Do not apply ACZONE Gel, 7.5% to eyes, mouth, or mucous membranes.

Manufactured for: Allergan, Inc. Irvine CA 92612, U.S.A.

By: DPT Laboratories, Ltd. San Antonio, TX 78215 U.S.A.

© 2016 Allergan. All rights reserved.

Irvine, CA 92612, U.S.A.

All trademarks are the property of their respective owners.

Patented. See: www.allergan.com/products/patent_notices

Made in the U.S.A.



-----Cut Here ✂-----

Patient Information
ACZONE® (AK-zōn) (dapsone) Gel, 7.5%

Important: For use on skin only (topical use). Do not use ACZONE Gel, 7.5% in your mouth, eyes, or vagina.

What is ACZONE Gel, 7.5%?

ACZONE Gel, 7.5%, is a prescription medicine used on the skin (topical) to treat acne in people 12 years and older. ACZONE Gel, 7.5%, has not been studied in children under 12 years of age.

Before you use ACZONE Gel, 7.5%, tell your doctor about all of your medical conditions, including if you:

- have a glucose-6-phosphate dehydrogenase deficiency (G6PD)
- have higher than normal levels of methemoglobin in your blood (methemoglobinemia)
- are pregnant or plan to become pregnant. It is not known if ACZONE Gel, 7.5% will harm your unborn baby.
- are breastfeeding or plan to breastfeed. ACZONE Gel, 7.5% can pass into your breast milk and may harm your baby. You and your doctor should decide if you will use ACZONE Gel, 7.5%, or breastfeed. You should not do both.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially, tell your doctor if you are using acne medicines that contain benzoyl peroxide. Use of benzoyl peroxide with ACZONE Gel, 7.5% at the same time may cause your skin or facial hair to temporarily turn yellow or orange at the site of application.

How do I use ACZONE Gel, 7.5%?

- Use ACZONE Gel, 7.5% exactly as your doctor tells you to use it.
- Apply ACZONE Gel, 7.5% one time a day.
- Gently wash and pat dry the areas of your skin where you will apply ACZONE Gel, 7.5%.
- Apply a pea-sized amount of ACZONE Gel, 7.5% in a thin layer to the entire face. A thin layer may also be applied to other affected areas as instructed by your doctor.
- Rub ACZONE Gel, 7.5% in gently and completely.
- Wash your hands after applying ACZONE Gel, 7.5%.
- If your acne does not get better after using ACZONE Gel, 7.5% for 12 weeks, talk to your doctor about continuing treatment.

What are the possible side effects of ACZONE Gel, 7.5%?

ACZONE Gel, 7.5% may cause serious side effects, including:

- **Decrease of oxygen in your blood caused by a certain type of abnormal red blood cell (methemoglobinemia).** Stop using ACZONE Gel, 7.5% and get medical help right away if your lips, nail beds, or the inside of your mouth turns grey or blue.
- **Breakdown of red blood cells (hemolytic anemia).** Some people with G6PD deficiency using ACZONE Gel, 7.5% may develop mild hemolytic anemia. Stop using ACZONE Gel, 7.5% and tell your doctor right away if you get any of the following signs and symptoms:
 - back pain
 - shortness of breath
 - tiredness or weakness
 - dark brown urine
 - fever
 - yellow or pale skin

The most common side effects of ACZONE Gel, 7.5% include dryness and itching of the skin being treated.

These are not all of the possible side effects of ACZONE Gel, 7.5%. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store ACZONE Gel, 7.5%?

- Store ACZONE Gel, 7.5%, at room temperature 68°F to 77°F (20°C to 25°C).
- Protect ACZONE Gel, 7.5% from freezing.

Keep ACZONE Gel, 7.5% and all medicines out of the reach of children.

General information about the safe and effective use of ACZONE Gel, 7.5%.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ACZONE Gel, 7.5% for a condition for which it was not prescribed. Do not give ACZONE Gel, 7.5% to other people, even if they have the same symptoms you have. It may harm them. You can ask your doctor or pharmacist for information about ACZONE Gel, 7.5% that is written for health professionals.

What are the ingredients in ACZONE Gel, 7.5%?

Active ingredient: dapsone

Inactive ingredients: diethylene glycol monoethyl ether, methylparaben, acrylamide/sodium acryloyldimethyl taurate copolymer, isohexadecane, polysorbate 80, and purified water.

Manufactured for: Allergan, Inc. Irvine CA 92612, U.S.A.
By: DPT Laboratories, Ltd. San Antonio, TX 78215 U.S.A.
© 2016 Allergan. All rights reserved.
Irvine, CA 92612, U.S.A.
All trademarks are the property of their respective owners.
Patented. See: www.allergan.com/products/patent_notices
Made in the U.S.A.



For more information, call 1-800-433-8871

This Patient Information has been approved by the U.S. Food and Drug Administration.

Issued: 02/2016